Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MGNX - Macrogenics Inc


IEX Last Trade
3.52
0.050   1.420%

Share volume: 1,276,805
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.47
0.05
1.44%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
26%
Profitability 25%
Dept financing 12%
Liquidity 73%
Performance 18%
Company vs Stock growth
vs
Performance
5 Days
0.57%
1 Month
-33.14%
3 Months
-17.22%
6 Months
-79.58%
1 Year
-28.37%
2 Year
-12.25%
Key data
Stock price
$3.52
P/E Ratio 
-1.61
DAY RANGE
N/A - N/A
EPS 
-$2.19
52 WEEK RANGE
$3.20 - $21.88
52 WEEK CHANGE
-$0.28
MARKET CAP 
220.155 M
YIELD 
N/A
SHARES OUTSTANDING 
62.722 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$643,021
AVERAGE 30 VOLUME 
$787,290
Company detail
CEO: Scott Koenig
Region: US
Website: https://www.macrogenics.com/
Employees: 415
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!

Recent news